Perceptions and Experiences of Patients Receiving Oral Chemotherapy

At a Glance
Patients in focus groups identified multiple safety and reli- ability concerns regarding the prescribing, dispensing, administering, and monitoring of oral chemotherapy.
Patients were concerned about the identification and man- agement of side effects from oral cancer therapy, particularly among pediatric patients.
Participants desired more comprehensive education at the  initial prescribing encounter and more frequent providerinitiated follow-up.
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Unfortunately, the use of oral cancer treatment appears to have expanded more quickly than the infrastructure needed to ensure safe care. A survey of 42 U.S. cancer centers found that many commonly employed safeguards for infusion chemotherapy, such as templated orders and clinician double-checks, are lacking for oral agents (Weingart et al., 2007) . Many centers had no formal protocols for monitoring oral drug adherence.
Ensuring the safe administration of oral cancer therapy poses a new challenge for patients as well. They have to navigate the process of securing medications from retail and mail-order pharmacies that are sometimes unfamiliar with the medications and then administer the drugs reliably without supervision (Weingart et al., 2008) . Adherence rates for oral cancer therapy range from less than 20% to 100%, depending on the drug and patient population (Levine et al., 1987; Love, Cameron, Connell, & Leventhal, 1991 
